Skip to main content

Military Health System

Innovative mobile technologies impact DOD health surveillance

Image of Medical personnel using a syringe to inject a fluid into a test tube. Dr. Peter Larson loads an Oxford Nanopore MinION sequencer in support of COVID-19 sequencing assay development at the U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland. (Photo by John Braun Jr., USAMRIID.)

Recommended Content:

Coronavirus & the MHS Response | Research and Innovation | Health Care Technology

The COVID-19 pandemic has highlighted the importance of collaboration and information-sharing forums for those working in the health field.

An example of one such forum is the Armed Forces Health Surveillance Division (AFHSD), Global Emerging Infections Surveillance (GEIS) Branch’s Next Generation Sequencing and Bioinformatics Consortium (NGSBC) and their mobile next generation sequencing (NGS) working group.

The NGSBC was created in 2017, bringing together DOD partners for coordination and improvement of pathogen genetic sequencing and analysis efforts. Subject matter experts from the Naval Medical Research Center, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Walter Reed Army Institute of Research, U.S. Air Force School of Aerospace Medicine, and the Naval Health Research Center assist the overseas service laboratories and other partners with protocol development, sample processing, and sequence data analysis.

As genetic sequencing capabilities have evolved and grown, so has the desire to have mobile platforms that could shorten the time from sample collection to final results reporting. Therefore GEIS and partners are exploring the use of mobile NGS technology in the laboratory, the field, and austere environments. To support these efforts, the mobile NGS working group was derived from the NGSBC in 2019 and focuses on increasing knowledge and use of mobile NGS technologies.

“This is a much needed working group to connect portable sequencing platform users across the DOD,” said Dr. Cory Bernhards, a member of the group who uses mobile NGS methods. “It will boost efficiency and foster collaboration among the different laboratories.”

The mobile NGS forum supports communication and collaboration between DOD and other government laboratories by creating a platform for partners to share protocols and provide training sessions. Participants meet regularly to discuss issues like how to address unique matters related to the way work is conducted in the field and not in a traditional lab - such as how to keep reagents and supplies at safe temperatures and how to perform remote complex computer-based data analysis. They also present use cases of pathogenic viruses including SARS-CoV-2 sequencing results from the Oxford Nanopore MinION, a type of mobile NGS technology.

“This working group will greatly accelerate progress toward fielding sequencing capabilities to serve and protect the warfighter,” said Bernhards.

The working group currently has more than 100 participants from 28 different organizations, including interagency partners from Centers for Disease Control and Prevention and Food and Drug Administration.

GEIS will continue to support partners in implementing capabilities for mobile NGS platforms, to set goals for using the technology, and to provide resources to address challenges. Navy Capt. Guillermo Pimentel, chief of GEIS, expressed his optimism for this mobile lab capability. 

"Having a mobile sequencing capability could provide an advantage in the early detection of an infectious disease that could negatively impact our deployed forces." Pimentel also highlighted the potential use of the technology, “The platform could also be used to determine if insects collected as part of regular vector surveillance carry viruses that could cause diseases in an operational setting."

You also may be interested in...

Consolidated Department of Defense Coronavirus Disease 2019 Force Health Protection Guidance

Policy

Consolidates and updates the Department’s guidance regarding vaccination verification, vaccination status, COVID-19 testing, surveillance and screening testing, personnel protection on-site mask requirements, (e.g., DHA military medical treatment facilities, meetings, travel), and the protection of personally identifiable information.

DHA-IPM 20-004: Department of Defense (DOD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation

Policy

Establishes the Defense Health Agency’s procedures to implement instructions, assign responsibilities, and prescribe procedures for the DHA’s implementation of the DOD’s COVID-19 Vaccination Program.

Coronavirus Disease 2019 Vaccination Attestation, Screening Testing, and Vaccination Verification

Policy

This memorandum provides guidance on the implementation of vaccination, attestation, and testing requirements in accordance with the References listed in Attachment 1 to reduce the transmission of the virus that causes COVID-19.

Medical Logistics Guidance for the DoD Coronavirus Disease 2019 (COVID-19) Vaccination Program

Policy

Establishes the DHA's procedures for ordering, receiving, and managing COVID-19 Vaccines inventory and ancillary kits for enduring COVID-19 support.

TAB A MEO COVID19 Medical Coding Policy

Policy

Memorandum for DHA Staff - Military Medical Treatment Facilities to Implement Updated DHA COVID-19 Medical Coding Policy

DHA COVID19 Medical Coding PolicyV5 1v

Policy

Establishes the DHA procedures to standardize the coding for Coronavirus 2019 (COVID-19) within military medical treatment facilities (MTFs). This memorandum replaces DHA-Policy Memorandum 20-003 of July 1, 2020. Attachment 1 was updated to include the 2021 procedure and diagnosis codes for COVID-19, including the new vaccination and treatment codes.

Supplemental Guidance for Providing DOD Coronavirus Disease 2019 Vaccines to DOD Contractor Employees and Select Foreign Nationals

Policy

This memorandum provides supplemental guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines, in accordance with reference (a). The Defense Health Agency (DHA) is the lead coordinating DOD Component for executing this guidance, in coordination with the Military Departments and other DOD Components as appropriate.

HA Guidance for Coronavirus Disease 2019 (COVID-19) Laboratory Pre-Testing Questionnaire

Policy

This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DOD beneficiaries treated at military medical treatment facilities.

Executive Order on Ensuring Access to United States Government COVID-19 Vaccines

Policy

This EO outlines who should receive priority access to COVID-19 vaccines developed in the United States or procured by the United States Government (“United States Government COVID-19 Vaccines”).

Coronavirus Disease 2019 Vaccine Guidance

Policy

This memorandum provides guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines. The Defense Health Agency (DHA) is the lead coordinating DOD Component for executing this guidance, in coordination with the Military Departments and other DOD Components.

Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 Environment

Policy

Establishes the DHA's plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic

Military Medical Treatment Facilities to Implement Updated DHA COVID-19 Medical Coding Policy

Policy

The Defense Health Agency (DHA) Memorandum, based on the authority of References (a) and (b), and in accordance with the guidance of References (c) and (d), establishes the DHA’s procedures to standardize the coding for Coronavirus 2019 (COVID-19) Military Medical Treatment Facilities (MTFs). This memorandum cancels and replaces DHA- Policy Memorandum 20-003 of (13 April 2020). A change was issued since the cancelled Memorandum 20-003 of (13 April 2020), the Attachment titles were updated to reflect that Attachments 1, 2, and 4 are considered Policies as opposed to Guidance.

Waiver of Restrictive Licensure and Privileging Procedures to Facilitate the Expansion of Telemedicine Services in the Military Health System 12-010

Policy

In order to facilitate the expansion of telemedicine services in the Military Health System, this memorandum waives selective provisions of Department of Defense 602S.13-R, "Clinical Quality Assurance in the Military Health System," June 11 , 2004. This waiver is conditioned on the specific provisions of this memorandum, and shall remain in effect, unless modified or revoked, until the cancellation and reissuance of DoD 602S.13-R, or the issuance of a Department of Defense Instruction for or including telemedicine.

MHS Enterprise Architecture Signed Memo and Guide 20120730

Policy

Announcement of the release of the Military Health System (MHS) Enterprise Architecture (EA) Guide. The guide supports the MHS CIO’s responsibilities for development and maintenance of EA, which complies with the Department of Defense’s responsibilities under the Clinger-Cohen Act of 1996, Public Law 104-106.

Guidance on the Establishment of a Human Cell, Tissue, and Cellular and Tissue Based Products Program

Policy

This memorandum requests the Services resource a Human Cell, Tissue, and Cellular and Tissue Based Products (HCT/Ps) Program that complies with regulatory standards for management and oversight of HCT/Ps, according to the best fit for their Service.

<< < 1 2 > >> 
Showing results 1 - 15 Page 1 of 2
Refine your search
Last Updated: February 02, 2021
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery